MOLN logo

Molecular Partners AG American Depositary Shares

MOLN

MOLN: Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

more

Show MOLN Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of MOLN by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MOLN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Designed ankyrin repeat domains with altered surface residues Feb. 14, 2023
  • Patent Title: Ankyrin repeat binding proteins and their uses Oct. 11, 2022
  • Patent Title: Designed ankyrin repeat proteins binding to hepatocyte growth factor Sep. 27, 2022
  • Patent Title: Recombinant binding proteins and their use May. 17, 2022
  • Patent Title: Recombinant binding proteins targeting her2 and serum albumin, and their uses Jul. 21, 2020
  • Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction May. 12, 2020
  • Patent Title: Binding proteins comprising at least two repeat domains against her2 Aug. 06, 2019
  • Patent Title: Capping modules for designed ankyrin repeat proteins Jun. 18, 2019
  • Patent Title: Recombinant binding proteins and their use Dec. 18, 2018
  • Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Dec. 26, 2017
  • Patent Title: Designed repeat proteins binding to serum albumin Oct. 03, 2017
  • Patent Title: Capping modules for designed ankyrin repeat proteins Aug. 01, 2017
  • Patent Title: Recombinant proteins that simultaneously bind hgf, vegf-a and serum albumin, comprising ankyrin repeat domains Oct. 04, 2016
  • Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Mar. 22, 2016
  • Patent Title: Designed repeat proteins binding to serum albumin Mar. 15, 2016
  • Patent Title: Capping modules for designed ankyrin repeat proteins Dec. 29, 2015
  • Patent Title: Designed ankyrin repeat proteins binding to platelet-derived growth factor Oct. 20, 2015
  • Patent Title: Binding proteins inhibiting the vegf-a receptor interaction Dec. 02, 2014
  • Patent Title: Modified binding proteins inhibiting the vegf-a receptor interaction Apr. 29, 2014
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of MOLN in WallStreetBets Daily Discussion

MOLN News

Recent insights relating to MOLN

CNBC Recommendations

Recent picks made for MOLN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MOLN

Corporate Flights

Flights by private jets registered to MOLN